Early predictors of microvascular complications in type 1 diabetic patients

Clinical Biochemistry

Volumn 42, Issue 13-14, 2009, Pages 1401-1406

  Abd El Maksoud, Awatif M ^a   El Hefnawy, Mohammed H ^b   Yahya, Shaymaa M M ^c   Seoudi, Dina M ^d   Abdel Ghaffar, Abdel Rahman B ^d   Eskander, Emad F ^c   Ahmed, Hanaa H ^c   Kamal, Ibrahim H ^d  

^a Nutrition Institute   (Egypt)

^b National Institute of Diabetes and Endocrinology   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d Ain Shams University   (Egypt)

Author keywords

Adipocytokines; Diabetic complications; Glycemic control indices; Inflammatory markers; Microalbuminuria

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; LEPTIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL EXAMINATION; DEMOGRAPHY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADOLESCENT; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERLEUKIN-6; KIDNEY FUNCTION TESTS; LEPTIN; MALE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; VASCULAR DISEASES;

EID: 69149099437     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.008     Document Type: Article

References (36)

1. Daneman D. Is the 'accelerator hypothesis' worthy of our attention?. Diabet. Med. 22 (2005) 115-117
2. Taguchi T., and Brownlee M. The biochemical mechanisms of diabetic tissue damage. In: Pickup J.C., and Williams (Eds). Textbook of Diabetes. 3rd ed. 2 (2003), Blackwell, Oxford 47.1-47.17
3. Leiter L.A. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res. 86 S2 (2005) S3-S14
4. Hofer S.E., Bennetts B., Chan A.K., Holloway B., Karschimkus C., Jenkins A.J., et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J. Diabetes Complicat. 20 (2006) 322-328
5. Okamoto Y., Arita Y., Nishida M., Muraguchi M., Ouchi N., Takahashi M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab. Res 32 (2000) 47
6. Zhang P., Wang Y., Fan Y., Tanq Z., and Wang N. Over expression of adiponectin receptors potentiates the anti-inflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler. Thromb. Vasc. Diab. 29 (2009) 67-74
7. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler. Suppl. 6 (2005) 7-14
8. Iwashima Y., Horio T., Kumada M., Suzuki Y., Kihara S., Rakugi H., et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am. J. Cardiol. 98 (2006) 1603-1608
9. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425
10. Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., and Schwartz M.W. Central nervous system control of food intake and body weight. Nature 443 (2006) 289-295
11. Haynes W.G., Morgan D.A., Walsh S.A., Mark A.L., and Sivitz W.I. Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. 100 (1997) 270-278
12. Sierra-Honigmann M.R., Nath A.K., and Murakami C. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
13. Ducy P., Amling M., and Takeda S. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
14. Chehab F.F., Lim M.E., and Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat. Genet. 12 (1996) 318-320
15. Lam Q.L.K., and Lu L. Role of leptin in immunity. Cell Mol. Immunol. 4 1 (2007) 1-13
16. Emilsson V., Liu Y.L., Cawthorne M.A., Morton N.M., and Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islet cells and direct inhibitory action of leptin on insulin secretion. Diabetes 46 (1997) 313-316
17. Jackson E.K., and Li P. Human leptin has natriuretic activity in the rat. Am. J. Physiol. 272 3 Pt 2 (1997) F333-F338
18. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 Suppl1 (2003) 5-20
19. Tobe S.W., Mcfarlane P.A., and Naimark D.M. Microalbuminuria in diabetes mellitus. CMAJ 167 5 (2003) 499-503
20. Cambiaso C.L., Collet-Cassart D., and Lievens M. Immunoassay of low concentrations of albumin in urine by latex particle counting. Clin. Chem. 34 2 (1998) 416-418
21. SPSS for Windows, (2001). Rel.11.0.Chicago, SPSS.
22. Saraheimo M., Forsblom C., Fagerud J., Teppo A., Pettersson-Fernholm K., Frystyk J., et al. Serum adiponectin is increased in type 1 diabetic subjects with nephropathy. Diabetes Care 28 6 (2005) 1410-1414
23. Risch L., Saely C., Hoefle G., Rein P., Langer P., Gouya G., et al. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin. Chim. Acta 376 (2007) 108-113
24. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351 13 (2004) 1296-1305
25. Wang Y., Xu A., Knight C., Xu L., and Cooper G. Hydroxylation and glycosylation of the four conserved tyrosine residues in their collagenous domain of adiponectin. J. Biol. Chem. 277 (2002) 19521-19529
26. Molitch M.E. American Diabetes Association, diabetic nephropathy. Diabetes Care 26 (2003) 94-S98
27. Huypens P., Moens K., Heimberg H., Ling Z., Pipeleers D., and Casteele M.V.D. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci. 77 (2005) 1273-1282
28. Fujita H., Mori T., Koshimura J., Ishika M., Kato M., Miura T., et al. Possible relationship between adiponectin and renal injury in diabetic nephropathy. Endocr. J. 53 6 (2005) 745-752
29. Nakanishi S., Yamane K., Kamei N., Nojima H., Okubo M., and Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 54 (2005) 194-199
30. Tartaglia L.A. The leptin receptor. J. Biol. Chem. 272 (1997) 6093-6096
31. Kratzsch J., Kner I., Galler A., Kapellen T., Raile K., Körner A., et al. Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor. Eur. J. Endocrinol. 155 (2006) 609-614
32. Zhang Y., Jiang J., Black R.A., Baumann G., and Frank S.J. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 141 (2000) 4342-4348
33. Kratzsch J., Deimel A., Galler A., Kapellen T., Klinghammer A., and Kiess W. Increased serum soluble leptin receptor levels in children and adolescents with type1 diabetes mellitus. Eur. J. Endocrinol. 151 (2004) 515-529
34. Nishikawa T., Edelstein D., and Du X.L. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404 (2000) 787-790
35. Beltowski J., Wojcicka G., and Jamroz A. Leptin decreases plasma paraoxonase 1(PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 170 (2003) 21-29
36. Huypens P. Leptin controls adiponectin production via the hypothalamus. Med. Hypotheses 68 (2007) 87-90